Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
Key facts
- Who runs it
- Virginia Commonwealth University
- Where
- Richmond, United StatesSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 14 Dec 2016
- Ended
- 27 Jan 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Natural history
- Record updated
- 11 March 2025
Who can take part
- Age
- 0 years to 15 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age 0-15 yrs
- Diagnosis of CDM, based on symptoms and genetic testing of expanded trinucleotide repeats
- Age 0-15 yrs
- Healthy children on no medication
Who cannot take part
- Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of site investigator
- Any illness or situation that, in the opinion of the site investigator, has the possibility to interfere with study procedures
- Significant trauma within one month
- Internal metal or devices; Control Group
- DM type 1 and 2
Other criteria
- CDM Group
Where in United States
Also in 2 other countries, 2 sites
- Virginia Commonwealth UniversityRichmond, United States
About the trial
What the trial wants to find out
Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay.
Read full original descriptionShow less
The investigators will enroll children with CDM between ages 0-15 with visits at baseline and one year to evaluate appropriate physical functional outcomes, cognitive function and quality of life over time. Functional outcome measures will be correlated with potential biomarkers in the children. Completion of these specific aims will extend the understanding of disease progression in CDM and will provide the requisite information for successful therapeutic trials in children with DM.
The 2 groups in the trial
- CDM
Children with Congenital Myotonic Dystrophy
Treatment: Natural history
- Control
Healthy Children
Treatment: Natural history
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 11 March 2025